Nervous System Origin Or Derivative Patents (Class 435/368)
  • Patent number: 10723997
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating chronic pulmonary disease, a pharmaceutical formulation containing the same, and a method for preparing the same, the composition comprising as an active ingredient an exosome derived from thrombin-treated stem cells. The therapeutic agent is advantageous in that since the therapeutic agent is a cell-free preparation, the risk of carcinogenesis is low and there is no problem of transplant rejection reaction, and furthermore, there is no possibility of causing the occlusion of the microvascular system upon systemic administration, and since the therapeutic agent is a non-cell separating material, it is possible to develop a pharmaceutical agent as an off-the-shelf product, thereby reducing the manufacturing cost, and the therapeutic agent has an excellent therapeutic effect for chronic pulmonary disease with a low concentration of exosome by virtue of the thrombin treatment effect.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: July 28, 2020
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Yun Sil Chang, Won Soon Park, Dong Kyung Sung, So Yoon Ahn
  • Patent number: 10578608
    Abstract: Some embodiments include a genetically engineered cell comprising a nucleic acid encoding a detectable polypeptide operably linked to the Msi1 or Msi2 promoter and genetically engineered organisms comprising these genetically engineered cells.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: March 3, 2020
    Assignee: The Regents of the University of California
    Inventor: Tannishtha Reya
  • Patent number: 10450546
    Abstract: The present disclosure relates to a preparation of CD140a/PDGFR? positive cells that comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFR?. The preparation of cells is derived from pluripotent cells that were derived from skin cells, fibroblasts, umbilical cord blood, peripheral blood, bone marrow, or other somatic cells. The cell preparation has an in vivo myelination efficiency that is equal to or greater than the in vivo myelination efficiency of a preparation of A2B5+/PSA-NCAM?sorted fetal human tissue derived oligodendrocyte progenitor cells. Methods of making, isolating and using the disclosed cell preparation are also described.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: October 22, 2019
    Assignee: University of Rochester
    Inventors: Steven A. Goldman, Su Wang
  • Patent number: 10227563
    Abstract: The present invention enables efficient suspension culture of stem cells in a serum-free medium by comprising a step for quickly forming homogenous aggregates of stem cells, and provides a method of selectively inducing the differentiation of nerves from a stem cell, a method of forming a cerebral cortical nerve network in vitro, and a method of producing a steric structure of a brain tissue in vitro, as well as a method of producing hypothalamic neuron progenitor cells, comprising culturing pluripotent stem cells as suspended aggregates in a serum-free medium that substantially does not contain a Nodal signal promoter, a Wnt signal promoter, an FGF signal promoter, a BMP signal promoter, retinoic acid and an insulin, and isolating hypothalamic neuron progenitor cells from the culture.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: March 12, 2019
    Assignee: RIKEN
    Inventors: Yoshiki Sasai, Takafumi Wataya, Mototsugu Eiraku
  • Patent number: 10125350
    Abstract: The present invention pertains to a method for the generation of neurotoxin-sensitive, neuronal differentiated cells comprising the steps of: a) cultivating tumor cells which are able to differentiate into neuronal cells in a culture medium under conditions and for a time which primes said tumor cells for neuronal differentiation; and b) cultivating the tumor cells primed for neuronal differentiation of a) in a differentiation medium having an osmolality of 100 to 270 mOsm/kg, and comprising (i) B27 supplement and/or (ii) N2 supplement, for at least 3 days, thereby obtaining neurotoxin-sensitive, neuronal differentiated cells. The invention further relates to neurotoxin-sensitive, neuronal differentiated cells obtainable by the method of the invention.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: November 13, 2018
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Karl-Heinz Eisele, Kai Harting
  • Patent number: 10065999
    Abstract: The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: September 4, 2018
    Assignee: Acorda Therapeutics, Inc.
    Inventor: Mark Marchionni
  • Patent number: 9943547
    Abstract: Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: April 17, 2018
    Assignee: MESOBLAST INTERNATIONAL SÀRL
    Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
  • Patent number: 9862925
    Abstract: The present invention concerns the use of a population of cells comprising: (a) neural precursor cells committed to an oligodendroglial fate; (b) uncommitted neural precursor cells (c) differentiated oligodendrocytes; or (d) a combination of any one of (a) to (c) for the treatment of CNS autoimmune diseases, or for the preparation of a pharmaceutical composition for treating CNS autoimmune diseases, the population of cells being derived from human pluripotent stem cells. The invention also provides methods for obtaining such populations of cells, namely, neural precursor cells committed to an oligodendroglial fate as well as differentiated oligodendrocytes which then can be used in the treatment of CNS autoimmune diseases. A preferred autoimmune disease in the context of the present invention is multiple sclerosis where the population of cells is administered to the CNS for local treatment of the disease.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: January 9, 2018
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventors: Michal Aharonowiz, Ofira Einstein, Benjamin Reubinoff, Tamir Ben-Hur
  • Patent number: 9820933
    Abstract: The present invention relates to a composition for stimulating hair growth or preventing hair loss, which contains a conditioned medium or extract of neural stem cells (NSCs) isolated from the ventricular zone of the human brain, and to a preparation method thereof. The conditioned medium or extract of neural stem cells according to the present invention contains various growth factors and cytokines, and thus has an excellent effect on the stimulation of hair growth. Thus, it is useful for hair growth stimulation and hair loss prevention.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: November 21, 2017
    Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Sunghoi Hong, In-Sik Hwang, Kyung-A Choi
  • Patent number: 9795652
    Abstract: Oligodendrocytes (OLs), the predominant cell type found in cerebral white matter, are essential for structural integrity and proper neural signaling. Very little is known concerning stroke-induced OL dysfunction. Infusion of human umbilical cord blood (HUCB) cells protects striatal white matter tracts in vivo and directly protects mature primary OL cultures from oxygen glucose deprivation (OGD). Microarray studies of RNA prepared from OL cultures subjected to OGD and treated with HUCB cells showed an increase in the expression of 33 genes associated with OL proliferation, survival, and repair functions, such as myelination. Immunohistochemistry showed antioxidant protein expression was upregluated in the ipsilateral white matter tracts of rats infused with HUCB cells 48 hrs after middle cerebral artery occlusion (MCAO). These results show expression of genes induced by HUCB cell therapy that could confer oligoprotection from ischemia.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: October 24, 2017
    Assignee: University of South Florida
    Inventors: Keith Ronald Pennypacker, Alison Elizabeth Willing
  • Patent number: 9777255
    Abstract: A method for the isolation, storage and retrieval of mature retinal cells is disclosed. The Method is applicable to adult mammalian cone cells, and more particularly human cone cells, and to healthy as well as pathological or otherwise altered cone cells. A kit for the isolation, storage and retrieval of mature retinal cells is also described.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: October 3, 2017
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Peter R. Macleish, Xiaoming Chen
  • Patent number: 9632076
    Abstract: This application provides devices for modeling ischemic stroke conditions. The devices can be used to culture neurons and to subject a first population of the neurons to low-oxygen conditions and a second population of neurons to normoxic conditions. The neurons are cultured on a porous barrier, and on the other side of the barrier run one or more fluid-filled channels. By flowing fluid with different oxygen levels through the channels, one can deliver desired oxygen concentrations to the cells nearest those channels.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: April 25, 2017
    Assignees: The Charles Stark Draper Laboratory, Inc., The University of South Florida
    Inventors: Anilkumar Harapanahalli Achyuta, Javier Cuevas, Shivshankar Sundaram, Chris Katnik
  • Patent number: 9599626
    Abstract: ATM kinase is shown to regulate proteasome-mediated protein turnover through suppression of the expression of the ubiquitin-like protein ISG15 (Interferon Stimulated Gene 15). Silencing of the ISG15 pathway restored both the ubiquitin and autophagy pathways, and the UV-mediated degradation of their substrates in A-T cells. The ATM kinase negatively regulates the ISG15 pathway, and the constitutively elevated ISG15 pathway induces proteinopathy in A-T cells, and in A-T patients. These findings indicate that proteasome-mediated protein degradation is impaired in A-T cells due to elevated expression of the ISG15 conjugation pathway, which contributes to progressive neurodegeneration in A-T patients. The ISG15 pathway is a new target for both detection and treatment of A-T Inhibitors if ISG15 expression can be used to inhibit or attenuate neurodegeneration in A-T patients.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: March 21, 2017
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventor: Shyamal D. Desai
  • Patent number: 9574176
    Abstract: The present invention provides a neural stem cell having increased passage ability and a method for manufacturing a neural stem cell having increased passage ability. A neural stem cell in which the N-type calcium channel gene is knocked out or the influx of Ca2+ via the N-type calcium channel is substantially absent can be passaged for at least 4 generations and maintains the differentiation potential into a nerve cell even after passage for 4 generations.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: February 21, 2017
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Norimasa Miyamoto, Yuichi Ono, Kana Namiki, Yoshitoshi Kasuya
  • Patent number: 9493739
    Abstract: The present invention relates to stem cells in which a gene that activates signaling is introduced and to a method for proliferating the stem cells. More specifically, the invention relates to a method of significantly increasing the ability of stem cells to proliferate, either by transfecting stem cells with the Notch intracellular domain (NICD) to activate the Notch signaling pathway, or by transfecting stem cells with the c-MET gene and treating the transfected stem cells with the HGF ligand protein to activate the c-MET/HGF signaling pathway. According to the present invention, as a result of activating the Notch signaling pathway or the c-MET/HGF signaling pathway, stem cells having an excellent ability to proliferate can be produced in large amounts. Particularly, since neural stem cells which have been difficult to culture in vitro can be proliferated in large amounts, thus the neural stem cells will be more useful for the preparation of cell therapeutic agents for treating cranial nerve diseases.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: November 15, 2016
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Do Hyun Nam, Seung Chyul Hong, Bong gu Kang, Kyeung Min Joo
  • Patent number: 9399759
    Abstract: In order to provide a method for producing neural stem cells easily and quickly by inducing differentiation of somatic cells directly into neurospheres, dedifferentiation factors are introduced into somatic cells, which are then cultured in suspension in the presence of growth factors to produce the neurospheres, thereby allowing the neural stem cells to be produced quickly without establishing iPS cells.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: July 26, 2016
    Assignee: Keio University
    Inventors: Wado Akamatsu, Hideyuki Okano
  • Patent number: 9309495
    Abstract: A homogenous, symmetrically dividing population of adherent neural stem cells is obtained from ES cells or foetal or adult brain isolates, using an activator of a signalling pathway downstream of a receptor of the EGF receptor family, optionally in combination with an activator of a signalling pathway downstream of an FGF receptor. The neural stem cell population is highly pure and retains the ability to differentiate into neurons after in excess of 100 passages.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: April 12, 2016
    Assignee: The University Court of The University of Edinburgh
    Inventors: Luciano Conti, Steven Michael Pollard, Austin Gerard Smith
  • Patent number: 9127270
    Abstract: This invention provides a cell pattern recovery tool comprising a base material layer having a surface subjected to easy adhesion treatment, a temperature responsive polymer layer that is provided on the base material layer and has a surface subjected to silane treatment, and a cell adhesion inhibiting material layer provided on the temperature responsive polymer layer. According to the present invention, a cell pattern can be rapidly recovered while maintaining the cell pattern stably and reliably under minimally invasive conditions for the cells.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: September 8, 2015
    Assignees: TOKYO WOMEN'S MEDICAL UNIVERSITY, DAI NIPPON PRINTING CO., LTD.
    Inventors: Teruo Okano, Masayuki Yamato, Tatsuya Shimizu, Masatoshi Kuroda
  • Patent number: 9074180
    Abstract: Pluripotent cells are maintained in a self-renewing state in serum-free culture medium comprising a MEK inhibitor, a GSK3 inhibitor and, optionally, an antagonist of an FGF receptor. Pluripotent cells are also maintained in a self-renewing state in serum-free culture medium comprising a MEK inhibitor and an antagonist of an FGF receptor.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: July 7, 2015
    Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH
    Inventors: Austin Gerard Smith, Qi-Long Ying
  • Patent number: 9074182
    Abstract: The invention provides methods for depleting extraneous phenotypes from a mixed population of cells comprising the in vitro differentiated progeny of primate pluripotent stem cells. The invention also provides mixed cell populations enriched for a target cell phenotype where the mixed cell population comprises the differentiated in vitro progeny of primate embryonic stem cells.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: July 7, 2015
    Assignee: Asterias Biotherapeutics, Inc.
    Inventors: Jane S. Lebkowski, Catherine Ann Priest, Ross M. Okamura
  • Publication number: 20150147301
    Abstract: The present invention relates to the seminal discovery of compositions and a method of producing NSC obtained from stem cells derived from parthenogenically activated human oocytes (phNSC). The phNSC of the invention maintain proliferative and differentiation potential during cultivation and expansion.
    Type: Application
    Filed: January 7, 2015
    Publication date: May 28, 2015
    Inventors: Ruslan Semechkin, Dmitry Isaev
  • Publication number: 20150132853
    Abstract: Methods for de-differentiating or altering the life-span of desired “recipient” cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.
    Type: Application
    Filed: June 11, 2014
    Publication date: May 14, 2015
    Applicant: Advanced Cell Technology, Inc.
    Inventor: Karen B. Chapman
  • Publication number: 20150126410
    Abstract: The invention relates in a first embodiment to a method for increasing the yield of replication-incompetent adenoviruses having at least a partial deletion in the E1-region, wherein said adenoviruses are generated in a production cell, the method comprising the steps of: (a) expressing in said production cell an adenoviral pIX polypeptide from a nucleic acid sequence encoding said adenoviral pIX polypeptide under the control of (i) at least a minimal endogenous pIX promoter and a heterologous promoter; or (ii) a heterologous promoter; and (b) expressing in said production cell the elements necessary for the production and assembly of said adenoviruses from corresponding coding sequences, thereby increasing the yield of said adenoviruses generated in said production cell in comparison to the yield of replication-incompetent adenoviruses having at least a partial deletion in the E1-region generated in said production cell in the absence of said nucleic acid sequence encoding said adenoviral pIX polypeptide.
    Type: Application
    Filed: July 4, 2013
    Publication date: May 7, 2015
    Inventors: Christian Thirion, Zsolt Ruzsics
  • Publication number: 20150118198
    Abstract: Methods are provided for treating and/or reducing the severity of multiple sclerosis in a human, by administering autologous mesenchymal stem cell-derived neural precursors. Also described is an in vitro method for differentiating mesenchymal stem-cell derived neural precursor oligodengroglial and neuronal cell types.
    Type: Application
    Filed: October 28, 2014
    Publication date: April 30, 2015
    Applicant: MULTIPLE SCLEROSIS RESEARCH CENTER OF NEW YORK
    Inventors: Saud A. SADIQ, Violaine K. Harris
  • Publication number: 20150118749
    Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGF? superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGF? superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.
    Type: Application
    Filed: December 29, 2014
    Publication date: April 30, 2015
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Masha IDELSON, Ruslana ALPER-PINUS, Alex OBOLENSKY, Eyal BANIN, Benjamin Eithan REUBINOFF
  • Publication number: 20150111902
    Abstract: This invention relates to methods for altering the splicing of mRNA in cells. In particular, this invention also relates to methods for increasing the ratio of wild type to misspliced forms of mRNA and corresponding encoded proteins in cells possessing a mutant gene encoding either the i) misspliced mRNA corresponding to the mutant protein or ii) a component in the splicing machinery responsible for processing the misspliced mRNA. In addition, this invention relates to treating individuals having a disorder associated with a misspliced mRNA, such as Familial Dysautonomia or Neurofibromatosis 1, by administering to such an individual a cytokinin such as kinetin.
    Type: Application
    Filed: May 19, 2014
    Publication date: April 23, 2015
    Applicant: The General Hospital Corporation
    Inventors: Susan A. Slaugenhaupt, James F. Gusella
  • Publication number: 20150093761
    Abstract: A Method for inducing human neural stem/progenitor cells to differentiate into oligodendrocyte progenitor cells and application thereof comprises following steps of: pre-treating neural stem cells derived from different resources in pre-treatment medium including bFGF and EGF for culturing; and inducing neural stem cells after pre-treating with inducing medium including PDGF-AA, bFGF and NT3, so as to differentiate into oligodendrocyte progenitor cells (OPCs). Main markers of the OPCs obtained by the method, such as NG2, O4, A2B5 and PDGFR, have a positive rate of 80˜90%. The OPCs obtained thereby is capable of proliferating steadily in the OPCs inducing medium for at least 10 generations and simultaneously maintaining biological characteristics thereof unchanged. The OPCs induced by the present invention can be applied in treating myelin-associated diseases or researching on drug screening.
    Type: Application
    Filed: July 1, 2014
    Publication date: April 2, 2015
    Inventor: Zuo Luan
  • Patent number: 8993320
    Abstract: An isolated expandable human neural stem or progenitor cell wherein the cell is a progenitor cells or stem cell, maintains its capability to differentiate into neurons, astrocytes, and oligodendrocytes, maintains its ability to differentiate into oligodendrocyte lineage cells efficiently throughout subsequent passages, and the cell expresses at least cell surface antigens CD133 and CD140?. Also provided is a method of in vitro culturing an expandable neural progenitor or stem cell isolated from a mammalian central nervous system, and the culture itself, wherein said cell maintains its capability to differentiate into neurons, astrocytes, and oligodendrocytes and its ability to differentiate into oligodendrocyte-lineage cells efficiently. In addition, a method of treating a condition caused by a loss of myelin or a loss of oligodendrocytes is provided as is a composition comprising an isolated expandable neural stem cell or one cultured by the methods of the invention.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: March 31, 2015
    Inventor: Tsuneo Kido
  • Publication number: 20150087541
    Abstract: The present invention is based in part on a chemically defined method of generating neural stem cells (NSCs) and dopaminergic (DA) neurons from human pluripotent stem cells (hPSCs). The DA neurons of the invention can be derived from hPSCs and NSCs. The present invention also provides reagents and kits useful for the derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells.
    Type: Application
    Filed: April 23, 2013
    Publication date: March 26, 2015
    Inventors: Rodolfo Gonzalez, Ibon Garitaonandia, Ruslan Semechkin
  • Publication number: 20150087058
    Abstract: The present invention relates to a stem cell culture medium which can be substituted for a conventional stem cell culture medium containing the heterologous protein fetal bovine serum, and more particularly to a stem cell culture medium containing a basal medium and a knockout serum replacement and a method of culturing stem cells using the same. According to the invention, a high purity of stem cells having a reduced ability to spontaneously differentiate can be obtained without having to use the heterologous protein fetal bovine serum and expensive growth factors (EGF and bFGF), and thus the efficacy of stem cell therapy can be significantly increased.
    Type: Application
    Filed: April 17, 2013
    Publication date: March 26, 2015
    Applicant: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventor: Do Hyun Nam
  • Publication number: 20150065560
    Abstract: The present invention relates to a one-vector expression system comprising a sequence encoding two polypeptides, such as tyrosine hydroxylase (TH) and GTP-cyclohydrolase 1 (GCH1). The two polypeptides can be should preferentially be expressed at a ratio between 3:1 and 15:1, such as between 3:1 and 7:1. The invention is useful in the treatment of catecholamine deficient disorders, such as dopamine deficient disorders including but not limited to Parkinson's Disease. Moreover, the present invention provides a method to deliver the vector construct in order to limit the increased production of the catecholamine to the cells in need thereof.
    Type: Application
    Filed: April 1, 2014
    Publication date: March 5, 2015
    Inventors: Tomas Björklund, Anders Björklund, Deniz Kirik
  • Patent number: 8962314
    Abstract: A pluripotent stem cell isolated from the lateral ventrical of the brain or choroid plexus is provided. Compositions and methods of isolating and using the cell also is provided.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: February 24, 2015
    Assignee: The Regents of the University of California
    Inventors: Ebenezer N. Yamoah, Dongguang Wei
  • Patent number: 8961962
    Abstract: The present invention relates to methods of promoting the survival of cells by treating the cells with acid ceramidase. A kit for promoting ex vivo cell survival is also disclosed, as is a method of predicting in vitro fertilization outcome of a female subject.
    Type: Grant
    Filed: January 7, 2008
    Date of Patent: February 24, 2015
    Assignee: Mount Sinai School of Medicine
    Inventors: Edward H. Schuchman, Efrat Eliyahu, Nataly Shtraizent, Xingxuan He
  • Publication number: 20150037885
    Abstract: The production of human retinal pigment epithelial cells having a step of incubating human pluripotent stem cells with binder molecules binding to terminal N-acetyllactosamine (Gal?1-4Glc NAc) and/or blood group H determinant type 2 (Fuc?1-2Gal?1-4Glc NAc). A method of using lectin ECA in a culture of human pluripotent stem cells in order to support the stem cells to differentiate into retinal pigment epithelial cells is also disclosed.
    Type: Application
    Filed: December 20, 2011
    Publication date: February 5, 2015
    Applicant: GLYKOS FINLAND OY
    Inventors: Heli Skottman, Heidi Hongisto, Hanna Hiidenmaa, Jukka Partanen, Kaija Alfthan
  • Patent number: 8945919
    Abstract: Disclosed herein are methods and compositions for the use of marrow adherent stem cells and their descendents; e.g., bone marrow-derived neural regenerating cells; in the treatment of various neurodegenerative disorders. In certain embodiments, bone marrow-derived neural regenerating cells transplanted to sites of neural degeneration stimulate growth and/or survival of host neurons.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: February 3, 2015
    Assignee: San Bio, Inc.
    Inventors: Keita Mori, Martha C. Bohn, Ciara Tate, Irina Aizman, Aleksandra Glavaski, Tamas Virag
  • Publication number: 20150030658
    Abstract: The present invention relates to biocompatible compositions for transplantation into a sub-retinal space of the human eye. The compositions include a biodegradable polyester film, preferably a polycaprolactone (PCL) film, and a layer of human retinal progenitor cells. The compositions of the invention can be used as scaffolds for the treatment a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.
    Type: Application
    Filed: January 22, 2013
    Publication date: January 29, 2015
    Inventors: Caio Regatieri, Petr Y. Baranov, Michael J. Young
  • Publication number: 20150031129
    Abstract: The present invention relates to stem cells in which a gene that activates signaling is introduced and to a method for proliferating the stem cells. More specifically, the invention relates to a method of significantly increasing the ability of stem cells to proliferate, either by transfecting stem cells with the Notch intracellular domain (NICD) to activate the Notch signaling pathway, or by transfecting stem cells with the c-MET gene and treating the transfected stem cells with the HGF ligand protein to activate the c-MET/HGF signaling pathway. According to the present invention, as a result of activating the Notch signaling pathway or the c-MET/HGF signaling pathway, stem cells having an excellent ability to proliferate can be produced in large amounts. Particularly, since neural stem cells which have been difficult to culture in vitro can be proliferated in large amounts, thus the neural stem cells will be more useful for the preparation of cell therapeutic agents for treating cranial nerve diseases.
    Type: Application
    Filed: July 22, 2014
    Publication date: January 29, 2015
    Inventors: Do Hyun NAM, Seung Chyul HONG, Bong gu KANG, Kyeung Min JOO
  • Patent number: 8940293
    Abstract: The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS).
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: January 27, 2015
    Assignee: Henry Ford Health System
    Inventors: Yi Li, Michael Chopp
  • Patent number: 8936908
    Abstract: The present invention relates to a method for the production of a permanent human cell line, wherein isolated primary human cells are transfected simultaneously with a sequence allowing the expression of at least one cell transforming factor and a sequence allowing the expression of at least one recombinant polypeptide.
    Type: Grant
    Filed: March 7, 2006
    Date of Patent: January 20, 2015
    Assignee: CEVEC Pharmaceuticals GmbH
    Inventors: Gudrun Schiedner, Christoph Volpers
  • Publication number: 20150017139
    Abstract: The present disclosure provides methods of generating neural stem cells from differentiated somatic cells. The present disclosure also provides induced neural stem cells generated using a subject method, as well as differentiated cells generated from a subject induced neural stem cell. A subject neural stem cell, as well as differentiated cells derived from a subject neural stem cell, is useful in various applications, which are also provided in the present disclosure.
    Type: Application
    Filed: July 18, 2014
    Publication date: January 15, 2015
    Inventors: Yadong Huang, Karen Ring
  • Patent number: 8927276
    Abstract: The present invention relates to a simplified process, which is shorter in time, for propagation of proliferating cells, such as e.g. progenitor or stem cells, by means of a biphasic culturing system having a differentiation supporting component and a proliferation supporting component, and to the use of the stem cell cultures obtained in this way for cell therapy purposes. The present invention invention describes a method, which is highly efficient to prime stem or progenitor cells to differentiation using non-attachment matrices and differentiation supporting component. The cells produced therefrom may be used to treat a variety of neurodegenerative disorders.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: January 6, 2015
    Assignee: Cellin Technologies OUE
    Inventors: Kaia Palm, Toomas Neuman
  • Publication number: 20150005369
    Abstract: Disclosed are methods of gene delivery using capsid-modified recombinant adeno-associated viral (rAAV) vectors. Exemplary methods are provided employing vectors that have altered affinity for heparin or heparin sulfate, as well as vectors, expression systems, and rAAV virions that lack functional VP2 protein expression, but are nevertheless, fully virulent. Also provided by the invention are methods employing the rAAV vector-based compositions, virus particles, host cells, and pharmaceutical formulations in the expression of selected therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in selected mammals, including organs, tissues, and human host cells.
    Type: Application
    Filed: July 8, 2014
    Publication date: January 1, 2015
    Inventors: Nicholas Muzyczka, Shaun R. Opie, Kenneth H. Warrington
  • Patent number: 8921107
    Abstract: The present invention provides a method for differentiating human neural progenitor cells into dopaminergic neurons, comprising the step of culturing human neural progenitor cells in a medium containing fusaric acid. In addition, the present invention provides a medium for differentiation of human neural progenitor cells into dopaminergic neurons.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: December 30, 2014
    Assignee: College of Medicine Pochon Cha University Industry-Academic Corportaion Foundation
    Inventor: Ji-Sook Moon
  • Patent number: 8916382
    Abstract: In one aspect, there is provided a cell culturing substrate including: a cell culture surface having a film attached thereto, wherein the film includes one or more plasma polymerized monomers; and a coating on the film-coated surface, the coating deposited from a coating solution comprising one or more extracellular matrix proteins and an aqueous solvent, where the total extracellular matrix protein concentration in the coating solution is about 1 ng/mL to about 1 mg/mL.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: December 23, 2014
    Assignee: Corning Incorporated
    Inventors: Suparna Sanyal, Deepa Saxena, Susan Xiuqi Qian, Elizabeth Abraham
  • Publication number: 20140370596
    Abstract: A homogenous, symmetrically dividing population of adherent neural stem cells is obtained from ES cells or foetal or adult brain isolates, using an activator of a signalling pathway downstream of a receptor of the EGF receptor family, optionally in combination with an activator of a signalling pathway downstream of an FGF receptor. The neural stem cell population is highly pure and retains the ability to differentiate into neurons after in excess of 100 passages.
    Type: Application
    Filed: July 21, 2014
    Publication date: December 18, 2014
    Inventors: Luciano Conti, Steven Michael Pollard, Austin Gerard Smith
  • Publication number: 20140370007
    Abstract: This disclosure generally relates to cell-based therapies for treatment of visual disorders, including disorders of the cornea. Methods are exemplified for directed differentiation of corneal cells from stem cells. Compositions of corneal endothelial cells and uses thereof are also provided. Exemplary compositions exhibit improved cell density and/or more “youthful” gene expression relative to cells obtained from donated tissue.
    Type: Application
    Filed: December 6, 2012
    Publication date: December 18, 2014
    Applicant: Advanced Cell Technology, Inc.
    Inventors: Kathryn L. McCabe, Shi-Jiang Lu, Robert P. Lanza
  • Publication number: 20140356291
    Abstract: IDH1-mutant cell lines and xenografts (e.g., IDH1R132H heterozygous and IDH1R132H homozygous) are derived from human glioblastoma multiforme (GBM) samples. Methods use said cells and xenografts as tools for determining the impact of IDH1R132H on cancer properties including cellular morphology, tumorigenesis, DNA, apoptosis, and metabolic profiles. Methods also use these cell lines for the screening and identification of candidate therapeutic targets.
    Type: Application
    Filed: December 10, 2012
    Publication date: December 4, 2014
    Applicant: DUKE UNIVERSITY
    Inventors: Hai Yan, Darell D. Bigner
  • Publication number: 20140356951
    Abstract: This document provides methods and materials related to differentiating iPS cells into glucose-responsive, insulin-secreting progeny. For example, methods and material for using indolactam V (ILV) and glucagon like peptide-1 (GLP-1) to produce glucose-responsive, insulin-secreting progeny from iPS cells are provided.
    Type: Application
    Filed: July 24, 2014
    Publication date: December 4, 2014
    Inventors: Tayaramma Thatava, Andre Terzic, Yogish C. Kudva, Yasuhiro Ikeda
  • Publication number: 20140356960
    Abstract: The present invention relates to a nucleic acid containing at least one homing endonuclease site (HE) and at least one restriction enzyme site (X) wherein the HE and X sites are selected such that HE and X result in compatible cohesive ends when cut by the homing endonuclease and restriction enzyme, respectively, and the ligation product of HE and X cohesive ends can neither be cleaved by the homing endonuclease nor by the restriction enzyme. Further subject-matter of the present invention relates to a vector comprising the nucleic acid of the present invention, host cells containing the nucleic acid and/or the vector; a kit for cloning and/or expression of multiprotein complexes making use of the vector and the host cells, a method for producing a vector containing multiple expression cassettes, and a method for producing multiprotein complexes.
    Type: Application
    Filed: April 25, 2014
    Publication date: December 4, 2014
    Inventor: Imre Berger
  • Patent number: 8895301
    Abstract: A transcription factor both necessary and sufficient for human neuroectoderm specification, Pax6, as well as applications thereof, is disclosed.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: November 25, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Su-Chun Zhang, Xiaoqing Zhang